Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Prelude Therapeutics ( (PRLD) ) has shared an update.
On January 9, 2026, Prelude Therapeutics began using a new corporate investor presentation outlining its strategy to advance two highly differentiated programs: JAK2V617F mutant-selective JH2 inhibitors for myeloproliferative neoplasms and first-in-class, highly selective oral KAT6A degraders for ER-positive breast cancer and other tumors. The materials highlight recently disclosed preclinical data showing potent, mutant-selective activity of its JAK2V617F inhibitors, positioning them as potential disease-modifying therapies in a large and growing market now dominated by first-generation agents such as ruxolitinib, and describe a planned Phase 1 program as well as an exclusive option agreement with Incyte announced in November 2025 that provides significant capital to support the JAK2V617F and KAT6A pipelines, alongside ongoing degrader payload discovery and partnering efforts.
The most recent analyst rating on (PRLD) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Prelude Therapeutics stock, see the PRLD Stock Forecast page.
Spark’s Take on PRLD Stock
According to Spark, TipRanks’ AI Analyst, PRLD is a Neutral.
PRLD’s score is held back primarily by weak financial performance—large ongoing losses, significant cash burn, and a materially reduced equity base. Offsetting this, technicals show a strong uptrend and positive momentum (though overbought), and the latest earnings call was supportive due to clearer development plans and the Incyte partnership extending financial runway; valuation remains constrained by the lack of profitability and no stated dividend yield.
To see Spark’s full report on PRLD stock, click here.
More about Prelude Therapeutics
Prelude Therapeutics is a clinical-stage oncology company focused on precision medicine, developing small-molecule and degrader-based therapies that precisely target oncogenic mechanisms in cancer. Its pipeline centers on first- or best-in-class programs for clinically validated targets, with a particular focus on JAK2V617F-driven myeloproliferative neoplasms and KAT6A in estrogen receptor–positive breast cancer and other malignancies, and it also operates a discovery engine for degrader antibody conjugates that can be partnered with larger biopharmaceutical companies.
Average Trading Volume: 1,468,189
Technical Sentiment Signal: Buy
Current Market Cap: $160.2M
Find detailed analytics on PRLD stock on TipRanks’ Stock Analysis page.